SIB2 Antibody

What is the difference between SIB2 and CIB2 proteins in research contexts?

When researchers discuss "SIB2 Antibody," they may be referring to antibodies against one of two distinct proteins: CIB2 (Calcium and integrin-binding family member 2) in mammals or Sib2 (ornithine-N5-oxygenase) in Schizosaccharomyces pombe (fission yeast). CIB2 is a 187 amino acid protein with three EF-hand domains involved in calcium binding and signaling, particularly in muscle tissue . In contrast, Sib2 in yeast functions as an ornithine-N5-oxygenase involved in the biosynthesis pathway of Fc . These proteins have different functions, structures, and evolutionary origins despite the similar nomenclature. When designing experiments, researchers should specify which protein they are targeting to avoid confusion.

What are the key biological functions of CIB2 that researchers investigate using these antibodies?

CIB2 plays significant roles in various cellular signaling pathways, particularly in muscle tissue. It interacts with integrins (especially integrin α7) and calcium to mediate cellular responses . CIB2 is closely related to CIB1, which is known for its role in platelet function and signal transduction. Researchers use CIB2 antibodies to investigate these protein-protein interactions, calcium binding via its three EF-hand domains, and its potential involvement in congenital muscular dystrophies like MDC1A . Proper experimental design should include controls to validate antibody specificity, comparison with known CIB2 expression patterns, and correlation with functional assays.

What experimental applications has the CIB2 antibody been validated for?

The CIB2 antibody (particularly CIB2C12B11) has been validated for western blotting (WB) and immunoprecipitation (IP) applications . When designing experiments, researchers should include positive controls (tissues/cells known to express CIB2) and negative controls (tissues/cells lacking CIB2 expression or samples treated with blocking peptides). Optimization protocols should include titration of antibody concentration, testing different blocking reagents, and varying incubation times and temperatures to determine optimal detection conditions for each application.

How can researchers validate the specificity of CIB2 antibody for their experimental system?

To validate CIB2 antibody specificity, researchers should implement multiple complementary approaches:

• Peptide competition assays – pre-incubating the antibody with excess immunizing peptide

• Knockout/knockdown controls – comparing detection in CIB2-expressing vs. CIB2-depleted samples

• Multiple antibody validation – using antibodies targeting different epitopes of CIB2

• Recombinant protein controls – comparing detection of purified recombinant CIB2

• Immunoprecipitation followed by mass spectrometry to confirm protein identity

Additionally, researchers should compare the observed molecular weight (approximately 21 kDa for human CIB2) with the expected weight and examine expression patterns across tissues known to express or lack CIB2 .

What factors might affect the reproducibility of results when using CIB2 antibody?

Several factors can affect inter-laboratory reproducibility when using CIB2 antibody:

Detailed methods reporting and standardized protocols are essential for reproducibility .

What are the recommended protocols for optimal CIB2 detection using Western blot analysis?

For optimal CIB2 detection via Western blot, the following protocol is recommended:

• Sample preparation: Use lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl₂, 0.1% Nonidet P-40, and protease inhibitor mixture

• Protein separation: Load 20-40 μg total protein per lane on 8-12% SDS-PAGE gels

• Transfer: Use standard wet transfer to PVDF membrane

• Blocking: Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Primary antibody: Dilute CIB2 antibody (CIB2C12B11) 1:1000 in blocking solution and incubate overnight at 4°C

• Washing: Wash 3x10 minutes with TBST

• Secondary antibody: Use HRP-conjugated anti-mouse IgG (for CIB2C12B11)

• Detection: Develop using ECL reagents and visualize via chemiluminescence

Include appropriate molecular weight markers (CIB2 runs at approximately 21 kDa), positive controls (muscle tissue), and loading controls (α-tubulin) .

How should researchers optimize immunoprecipitation protocols with CIB2 antibody?

To optimize immunoprecipitation protocols with CIB2 antibody:

• Cell lysis: Use gentle lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl₂, 0.1% Nonidet P-40, protease inhibitors) to preserve protein-protein interactions

• Pre-clearing: Pre-clear lysate with protein A/G beads to reduce non-specific binding

• Antibody binding: Incubate CIB2 antibody with protein lysate overnight at 4°C with gentle rotation

• Bead binding: Add protein A/G beads and incubate for 2-4 hours at 4°C

• Washing: Wash 4-5 times with lysis buffer containing reduced detergent

• Elution: Elute with 2X SDS sample buffer at 95°C for 5 minutes

Critical controls include: IgG isotype control, input sample (5-10% of starting material), and when possible, a CIB2-knockout/knockdown sample . For co-IP studies investigating CIB2 interactions with integrins or calcium-regulated proteins, consider using calcium-containing or chelating buffers to test calcium-dependence.

What experimental design is recommended for investigating CIB2-integrin interactions?

For investigating CIB2-integrin interactions:

• Co-immunoprecipitation: Use CIB2 antibody to pull down protein complexes, then probe for integrin α7 (or vice versa)

• Proximity ligation assay (PLA): Use antibodies against CIB2 and integrin α7 to visualize protein proximity in situ

• Calcium dependence: Perform experiments with varying calcium concentrations to determine if interactions are calcium-dependent

• Domain mapping: Express truncated versions of CIB2 (particularly EF-hand domains) and test interaction with integrins

• Competition assays: Determine if CIB1 competes with CIB2 for integrin binding

• Controls: Include IgG isotype controls, CIB2/integrin knockdown controls, and calcium chelation controls

This multi-method approach provides robust evidence for physiologically relevant interactions and identifies the specific conditions under which they occur.

What could cause the absence of CIB2 signal in Western blot despite proper sample preparation?

Several factors could cause absent CIB2 signal despite proper sample preparation:

• Antibody issues – degradation, improper storage, or lot-to-lot variation

• Epitope masking – post-translational modifications or protein-protein interactions blocking the epitope

• Low expression levels – CIB2 may be expressed at levels below detection limits in certain tissues

• Protein degradation – improper sample handling or insufficient protease inhibitors

• Transfer problems – inefficient transfer of low molecular weight proteins like CIB2

• Detection sensitivity – ECL reagents may be expired or insufficiently sensitive

• Species cross-reactivity issues – antibody may not recognize the species-specific epitope

• Wrong molecular weight region – examining incorrect region of the blot (CIB2 is ~21 kDa)

Troubleshooting approaches include: loading more protein, using more sensitive detection methods, trying different antibody concentrations, running positive control samples (tissues known to express CIB2), and verifying CIB2 expression with RT-PCR before protein analysis .

How should researchers interpret differences in CIB2 expression patterns between normal and disease tissues?

When interpreting differences in CIB2 expression between normal and disease tissues (such as muscular dystrophies), researchers should consider:

• Quantitative analysis – normalize CIB2 signals to loading controls and perform statistical analysis

• Pattern analysis – determine if changes are global or tissue-specific

• Correlation analysis – examine how CIB2 changes correlate with disease severity markers

• Time course analysis – track CIB2 expression across disease progression

• Mechanism validation – determine if changes are transcriptional or post-transcriptional

• Functional correlation – associate CIB2 changes with calcium handling or integrin signaling alterations

• Contextual analysis – compare with changes in related proteins like CIB1 or integrin α7

• Validation in multiple models – confirm findings across different disease models or patient samples

These approaches help distinguish causative changes from compensatory responses or secondary effects.

How can CIB2 antibody be used to study the role of CIB2 in congenital muscular dystrophies?

To study CIB2's role in congenital muscular dystrophies:

• Expression profiling – quantify CIB2 protein levels across different dystrophy models and patient biopsies

• Localization analysis – examine changes in CIB2 distribution within muscle fibers

• Co-localization studies – determine if CIB2 co-localizes with dystrophin, integrins, or other structural proteins

• Protein-protein interaction changes – investigate if CIB2 interactions with binding partners (particularly integrin α7) are altered in dystrophic conditions

• Calcium handling – combine CIB2 detection with calcium imaging to correlate CIB2 levels with calcium dysregulation

• Intervention studies – track CIB2 expression following therapeutic interventions

• Animal models – create CIB2 manipulation models to determine if modulating CIB2 affects dystrophic phenotypes

• Transcriptional regulation – investigate mechanisms controlling CIB2 expression in dystrophic conditions

CIB2 expression is significantly reduced in conditions such as Laminin α-2 chain deficiency, suggesting involvement in the pathogenesis of congenital muscular dystrophies like MDC1A .

What methodological approaches can combine CIB2 antibody detection with functional calcium signaling assays?

To combine CIB2 antibody detection with calcium signaling assays:

• Sequential analysis – perform calcium imaging followed by fixation and immunostaining for CIB2

• Live-cell approaches – use fluorescently-tagged CIB2 antibody fragments with calcium indicators

• Calcium manipulation – treat samples with calcium modulators, then detect CIB2 localization changes

• Correlative microscopy – perform calcium imaging, then process for electron microscopy with immunogold CIB2 labeling

• Calcium-dependent immunoprecipitation – perform CIB2 immunoprecipitation under varying calcium conditions

• Single-cell analysis – combine calcium imaging with single-cell isolation and CIB2 protein quantification

• FRET-based approaches – develop assays using tagged CIB2 to detect conformational changes upon calcium binding

• Calcium channel modulation – modify calcium channel activity and assess effects on CIB2 expression

These approaches allow researchers to correlate CIB2's calcium-binding properties with its functional roles in signaling pathways.

How can researchers design experiments to differentiate the functions of CIB2's three EF-hand domains?

To differentiate functions of CIB2's three EF-hand domains:

• Domain-specific antibodies – generate or obtain antibodies targeting specific EF-hand domains

• Mutant expression systems – express wild-type CIB2 alongside versions with mutations in specific EF-hand domains

• Calcium-dependent binding assays – perform pull-downs under varying calcium concentrations

• Conformational antibodies – develop antibodies that recognize calcium-bound vs. calcium-free conformations

• Competition assays – use peptides mimicking specific EF-hand domains to compete with full-length CIB2

• Domain swapping – create chimeric proteins swapping EF-hand domains between CIB1 and CIB2

• Structural studies – combine antibody epitope mapping with structural biology techniques

• Rescue experiments – in CIB2-depleted systems, reintroduce variants with specific EF-hand mutations

The three EF-hand domains of CIB2 are critical for calcium binding and likely mediate different aspects of CIB2 function in calcium signaling pathways .